secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001104659-23-034843
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx BeAT-HF trial: safety endpoint met, symptom improvement shown; primary endpoint not significant
--------------------------------------------------------------------------------

- Safety: MANCE event-free rate of 97% (p<0.001).
- Symptom improvement: 6-min walk +44m at 12mo, QoL +10 pts at 24mo (p<0.001).
- Primary endpoint (CV death, LVAD, transplant, HF hospitalizations) not significant (RR 0.94, p=0.82).
- All-cause mortality showed 34% relative reduction favoring BAT (HR 0.66, p=0.054).
- CEO plans FDA submission in coming months for expanded labeling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/0001104659-23-034843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/tm2310097d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-034843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer